The 60-Day Trap: A Working Guide to Medicare Advantage Appeal Deadlines, Every Step Explained

The letter ran eleven pages. The denial reason sat on page two. The sentence that mattered most, the one explaining that he had sixty days from the date printed at the top to ask for a reconsideration, was buried on page nine under a heading called "Your Appeal Rights." This was the letter a Mesa, Arizona orthopedist's MRI order produced when the patient's Medicare Advantage plan reviewed it in February: a stack of paper too long to read in one sitting, written for a 71-year-old retired bus driver who already had a stack of his wife's post-surgical bills on the same dining-room table. He set the new letter on top of the old ones. Nine weeks passed before his daughter called the plan on his behalf. By then the document had done what eleven-page denial letters tend to do. The window had closed. The plan told her, politely, that the case was no longer appealable at Level 1.

The sequence is common. KFF's analysis of CMS appeals data found that fewer than 12 percent of Medicare Advantage prior-authorization denials are ever appealed, even though the share of appeals that succeed runs well above the share most patients assume. The Medicare Payment Advisory Commission, in its March 2024 report to Congress, noted that Medicare Advantage plans denied roughly 3.4 million prior-authorization requests in 2022, a figure that has grown each year since CMS began collecting the data. The appeals process exists. The 60-day clock that controls access to it is the single most-missed detail in the entire regime.

Why Medicare Advantage is different from everything else

Most patients with prior insurance experience expect a 180-day appeal window, because that is the deadline under the Affordable Care Act framework and under ERISA self-funded employer plans. Medicare Advantage runs on a shorter clock. The deadline to file a Level 1 reconsideration is 60 days from the date on the denial notice, set by 42 CFR 422.582. There is a "good cause" extension, codified at the same section, but it is granted at the plan's discretion and is not a deadline a patient should rely on. A 2024 OMHA workload report flagged late-filing dismissals as one of the most common procedural reasons cases never reach the merits.

Three other features make Medicare Advantage appeals structurally different from commercial appeals. First, the process has five levels, not the two-or-three most patients expect. Second, the second-level review, after the plan reconsiders and upholds, goes automatically to an external Independent Review Entity contracted by CMS, not to a state-run external-review organization. Third, the IRE reversal rate is meaningfully higher than the plan's own reconsideration rate, which means dropping out at Level 1 leaves real coverage on the table. The structure rewards patients who stay in. It punishes patients who stop early.

The five levels, in order

Level 1 is the plan-level reconsideration. The patient, the provider acting on the patient's behalf, or an appointed representative files a written request with the Medicare Advantage plan within 60 days of the denial date. The plan must decide within 30 days on a pre-service request, 60 days on a payment request, and 72 hours on an expedited request where waiting could jeopardize the patient's health. These timeframes come from 42 CFR 422.590 and 42 CFR 422.584. If the plan upholds the denial in whole or in part, the case advances automatically to Level 2. The patient does not have to file a second request. CMS built this auto-forwarding rule into 42 CFR 422.590(d) precisely because patient drop-off at this stage was so high before the rule existed.

Level 2 is the Independent Review Entity. The IRE is a CMS contractor, currently Maximus Federal Services under its long-running contract for Part C reconsiderations, and it reviews the case on the record built at Level 1. The standards are set at 42 CFR 422.592. The IRE decision is binding on the plan. If the IRE reverses, the plan must authorize the service or pay the claim. The patient does not pay the IRE.

Level 3 is the Administrative Law Judge hearing at the Office of Medicare Hearings and Appeals. The patient has 60 days from the IRE decision to request a hearing, under 42 CFR 422.602. The case must meet an amount-in-controversy threshold, which CMS updates each year and which is $200 for calendar year 2026, per the Federal Register notice 2025-21879 published December 4, 2025. ALJ hearings are typically held by phone or video. The patient may appear with a representative, including counsel, but is not required to.

Level 4 is review by the Medicare Appeals Council at the Departmental Appeals Board. The patient has 60 days from the ALJ decision to request Council review, under 42 CFR 422.608. The Council reviews the ALJ record and may affirm, reverse, modify, or remand. There is no in-person hearing at this level in the ordinary case.

Level 5 is judicial review in federal District Court. The patient has 60 days from the Council decision to file, under 42 CFR 422.612. The amount-in-controversy threshold for judicial review is higher than the ALJ threshold and is also updated annually by CMS.

The sequence is consistent. The deadlines are consistent. Every level after Level 1 runs on the same 60-day clock. A patient who lets one deadline slip can lose the entire case regardless of how strong the underlying merits are.

Exhibit 1: The five-level funnel

The pattern that shows up across every published CMS dataset is steep attrition at Level 1, modest attrition at Level 2, and very small numbers at Levels 3 through 5. Reasonable estimates, drawing on KFF's analysis of CMS reporting and on OMHA's annual workload reports, look roughly like this.

| Level | Stage | Approximate share of original denials that reach this stage | |---|---|---| | 0 | Denial issued | 100% | | 1 | Plan reconsideration filed | 11% | | 2 | IRE review (auto-forwarded after plan upholds) | 4% | | 3 | ALJ hearing requested | <1% | | 4 | Medicare Appeals Council | very small | | 5 | Federal District Court | rare |

Action title for designer: "Nine in ten Medicare Advantage denials never get a second look. The funnel collapses at Level 1, before most patients know the plan owes them a second review."

Exhibit 2: Reversal rates at Level 1 versus Level 2

The reversal rate at the plan level and at the IRE level diverge in a way that explains why staying in the process matters. KFF's analysis of CMS Part C reconsideration data for the 2023 reporting year found that Medicare Advantage plans fully or partially overturned roughly 81 to 82 percent of the prior-authorization denials that were actually appealed. That figure looks generous until you remember that it conditions on filing, which fewer than one in eight patients do. At Level 2, IRE reversal rates published in CMS Part C Reconsideration Project reports have run in the broad range of 60 to 75 percent of the cases the IRE reaches, depending on category and year, with prior-authorization and procedural denials reversing at the high end and medical-necessity denials at the low end.

| Denial type | Plan-level (Level 1) overturn, of appealed cases | IRE (Level 2) overturn, of forwarded cases | |---|---|---| | Prior authorization | roughly the majority | roughly most | | Medical necessity | roughly 55-65% | roughly 50-60% | | Step therapy / formulary | roughly 70-80% | roughly 60-70% |

Action title for designer: "Medicare Advantage plans reverse most appeals they receive. The IRE reverses most of the ones the plan refuses to. Patients who stop after Level 1 lose access to the higher of the two reversal rates."

The ranges are deliberate. Public reporting from CMS, KFF, and the HHS Office of Inspector General has used different denominators in different years, and the figures move year to year. The directional point holds across every published dataset: the second look is materially more favorable to patients than the first.

Exhibit 3: The 60-day cascade

Every level after the initial denial runs on a 60-day filing clock, anchored to the date on the most recent decision letter. A patient who tracks the dates can keep a case alive for a year or more without ever missing a window. A patient who does not can lose the case at any of five points.

| Stage | Filing deadline | Source | |---|---|---| | Plan reconsideration (Level 1) | 60 days from denial notice date | 42 CFR 422.582 | | Plan decision on Level 1 | 30 days pre-service, 60 days payment, 72 hours expedited | 42 CFR 422.590, 422.584 | | Auto-forward to IRE | triggered automatically when plan upholds | 42 CFR 422.590(d) | | ALJ request (Level 3) | 60 days from IRE decision | 42 CFR 422.602 | | Medicare Appeals Council (Level 4) | 60 days from ALJ decision | 42 CFR 422.608 | | Federal District Court (Level 5) | 60 days from Council decision | 42 CFR 422.612 |

Action title for designer: "Five deadlines, every one of them 60 days. The Medicare Advantage appeals process is not complicated. It is unforgiving."

Why the work is heavier than it appears

Medicare Advantage layers procedural traps over short clocks. The Subpart M framework has more than two hundred distinct carrier-by-denial-type cells Apellica has catalogued, each running on its own Evidence of Coverage section, its own preferred medical-policy bulletin, its own internal routing for reconsideration. The indexed Administrative Law Judge precedent library that covers Subpart M Level 3 cases is the appeal lawyer's working reference. None of it is on the carrier's website.

The 60-day Level 1 deadline does not wait for medical records to arrive. The 72-hour expedited window requires a treating-physician attestation drafted in a specific clinical register; a request that fails the urgency threshold gets routed to the standard track and the patient loses the time. The four-hour hospital-discharge expedited window under 42 CFR 422.622 has its own form, fax route, and reviewer queue. Procedural exhaustion missteps at Level 1 or Level 2 can foreclose the ALJ hearing at Level 3 and the federal civil action at Level 5.

The auto-forward to the IRE sounds patient-friendly, and it is, but the record the IRE reviews is the record the patient built at Level 1. An incomplete Level 1 file produces an adverse IRE ruling the patient cannot supplement later. The Medicare Advantage carrier's reviewer is paid full-time to uphold denials. The patient is 71, on a fixed income, sometimes recovering from the surgery the appeal is fighting to cover, and trying to read an eleven-page denial letter at the kitchen table.

Sixty days is the only number in this regime the patient cannot negotiate.

What Apellica brings that a patient cannot

Apellica's reviewers work from a mapped library of over two hundred carrier-by-denial-type cells that tracks Medicare Advantage plan behavior at every level of Subpart M. The same desk maintains the indexed Administrative Law Judge precedent library, which surfaces the controlling decisions for any Medicare Advantage appeal heading to Level 3.

Same-day document-request letters go out with the correct CFR cites and the right delivery method for the carrier (carrier portal, certified mail, or the CMS-mandated form). Apellica's senior reviewers build the four-part evidence stack for every case, plan-language citation, clinical facts, peer-reviewed evidence, regulatory hook. The expedited-reconsideration attestation is drafted to meet the carrier's specific urgency standard, not the generic one. A senior reviewer reads every case before it goes out.

Initial review is free. There is no upfront fee. Patients are not asked to pay anything until the carrier reverses the denial.

Where the regime quietly works in patients' favor

Three rules tucked into Subpart M are worth knowing because they make the case stronger and most patients never hear about them.

The first is auto-forwarding at Level 1. If the plan does not meet its decision deadline, the case is treated as adverse and forwarded to the IRE automatically. Plans that miss the clock lose the case. This is in 42 CFR 422.590(d).

The second is the right of a treating physician to file the appeal on the patient's behalf, including the expedited request, without a formal appointment of representative form. This is in 42 CFR 422.584(b). For patients too ill to manage paperwork, the treating physician is the fastest route into the appeals process.

The third is the rule, set by 42 CFR 422.618 and 422.619, that a favorable IRE or ALJ decision must be effectuated, meaning the plan must authorize the service or pay the claim within specified timeframes after the decision. A reversal is not a recommendation. It is binding.

Where to ask for help

Free help exists at every level of this process, and the denial letter will not list most of it.

Every state operates a State Health Insurance Assistance Program, the SHIP network, funded by the Administration for Community Living, with trained counselors who help Medicare beneficiaries navigate appeals at no cost. The national directory is at shiphelp.org. The Medicare Rights Center, at medicarerights.org, runs a national consumer hotline at 800-333-4114 and publishes the most-used plain-English guide to the Medicare appeals process. The Center for Medicare Advocacy, at medicareadvocacy.org, focuses on systemic issues and case-level help for the most complex appeals, including skilled-nursing and home-health denials. The CMS Consumer Assistance line, 1-800-MEDICARE, can confirm appeal status and route procedural questions. State Departments of Insurance handle complaints against Medicare Advantage plans on issues that overlap with state-regulated conduct; the NAIC consumer site, content.naic.org/consumer.htm, lists every state contact. Apellica, at apellica.com, prepares evidence-based appeal letters for Medicare Advantage denials in all 50 states with no upfront fee.

Most patients call one of these once and never need to call back. The hard part is finding the right one on the first try.

What to do if you have a Medicare Advantage denial right now

The clock starts when the carrier dated the letter. Most patients calendar the wrong day. Patients who run a case to Level 2 see materially higher reversal rates than patients who stop at Level 1.

Most patients leave coverage on the table because the appeal is more procedural work than they can take on.

The Mesa retiree's nine-week delay was, in the regime's own arithmetic, twenty-nine days too long. His daughter is now filing the Level 1 reconsideration under the good-cause extension, with no guarantee the plan will accept it.

The Apellica model, briefly

Apellica prepares the evidence-based appeal letter for Medicare Advantage denials at every level from the plan reconsideration through the Medicare Appeals Council. The patient reviews and approves every word before submission and authorizes carrier communications under a HIPAA-compliant Assignment of Benefits. We are not a law firm. We are not a medical provider. We are not an insurance carrier. We are an independent administrative service that turns a denied claim into a properly documented appeal letter.

Our model is $0 upfront and a flat fee on successful recovery. If the appeal does not reverse, the patient owes nothing for the preparation work. Coverage extends to all 50 states, every Medicare Advantage plan, and every level of the Subpart M appeals process. A senior reviewer reads every case before it goes out.

About the author

The author, Mark Henderson, reviews insurance-denial appeals at Apellica, an independent administrative service that operates out of One World Trade Center, Suite 8500, in New York. Apellica works in all fifty states. The service does not practice law, does not provide medical care, and does not underwrite insurance. Questions go to press@apellica.com or +1 (888) 777-6120. The website is apellica.com.

References

• 42 CFR Part 422, Subpart M. Medicare Advantage Grievances, Organization Determinations, and Appeals.
• 42 CFR 422.566. Organization determinations.
• 42 CFR 422.578. Right to a reconsideration.
• 42 CFR 422.582. Request for a standard reconsideration.
• 42 CFR 422.584. Expediting certain reconsiderations.
• 42 CFR 422.590. Timeframes and notice requirements for reconsiderations.
• 42 CFR 422.592. Reconsideration by an independent entity.
• 42 CFR 422.602. Right to an ALJ hearing.
• 42 CFR 422.608. Medicare Appeals Council review.
• 42 CFR 422.612. Judicial review.
• Office of Medicare Hearings and Appeals, FY 2026 Adjustment of the Amount in Controversy Threshold Amounts (Federal Register notice).
• KFF, "Medicare Advantage Insurers Made Nearly 50 Million Prior Authorization Determinations in 2023." kff.org.
• Medicare Payment Advisory Commission, March 2024 Report to Congress, chapter on Medicare Advantage.
• HHS Office of Inspector General, OEI-09-18-00260, "Some Medicare Advantage Organization Denials of Prior Authorization Requests Raise Concerns."
• Medicare Rights Center. medicarerights.org.
• State Health Insurance Assistance Program (SHIP) national directory. shiphelp.org.
• Center for Medicare Advocacy. medicareadvocacy.org.
• NAIC Consumer Information Source. content.naic.org/consumer.htm.